Literature DB >> 20484092

Do men make informed decisions about prostate cancer screening? Baseline results from the "take the wheel" trial.

Jennifer D Allen1,2, Megan K D Othus3, Alton Hart4, Anshu P Mohllajee1, Yi Li1,3, Deborah Bowen5.   

Abstract

BACKGROUND: Baseline data from a randomized trial in 12 worksites were analyzed. Men aged 45+ (n = 812) completed surveys documenting screening history, screening preferences and decisions, CaP knowledge, decision self-efficacy, and decisional consistency. Psychosocial and demographic correlates of IDM were also assessed.
RESULTS: Approximately half of the sample had a prior PSA test, although only 35% reported having made an explicit screening decision. Across the sample, CaP knowledge was low (mean = 56%), although decision self-efficacy was high (mean = 78%), and the majority of men (81%) made decisions consistent with their stated values. Compared with those who were undecided, men who made an explicit screening decision had significantly higher levels of knowledge, greater decisional self-efficacy, and were more consistent in terms of making a decision in alignment with their values. They tended to be white, have high levels of income and education, and had discussed screening with their health care provider.
CONCLUSIONS: Many men undergo CaP screening without being fully informed about the decision. These findings support the need for interventions aimed at improving IDM about screening, particularly among men of color, those with lower levels of income and education, and those who have not discussed screening with their provider.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484092      PMCID: PMC4386607          DOI: 10.1177/0272989X10369002

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  43 in total

1.  Educating African American men about the prostate cancer screening dilemma: a randomized intervention.

Authors:  Kathryn L Taylor; Jackson L Davis; Ralph O Turner; Lenora Johnson; Marc D Schwartz; Jon F Kerner; Chikarlo Leak
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

Review 2.  Measures used in studies of informed decision making about cancer screening: a systematic review.

Authors:  Patricia Dolan Mullen; Jennifer Dacey Allen; Karen Glanz; Maria E Fernandez; Deborah J Bowen; Sandi L Pruitt; Beth A Glenn; Michael Pignone
Journal:  Ann Behav Med       Date:  2006-12

3.  Do social network characteristics predict mammography screening practices?

Authors:  Jennifer D Allen; Anne M Stoddard; Glorian Sorensen
Journal:  Health Educ Behav       Date:  2007-07-09

Review 4.  Screening for prostate cancer. American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1997-03-15       Impact factor: 25.391

5.  Assessing values for health: numeracy matters.

Authors:  S Woloshin; L M Schwartz; M Moncur; S Gabriel; A N Tosteson
Journal:  Med Decis Making       Date:  2001 Sep-Oct       Impact factor: 2.583

6.  The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test.

Authors:  D L Frosch; R M Kaplan; V Felitti
Journal:  J Gen Intern Med       Date:  2001-06       Impact factor: 5.128

7.  A new scale for assessing perceptions of chance: a validation study.

Authors:  S Woloshin; L M Schwartz; S Byram; B Fischhoff; H G Welch
Journal:  Med Decis Making       Date:  2000 Jul-Sep       Impact factor: 2.583

8.  Videotape-based decision aid for colon cancer screening. A randomized, controlled trial.

Authors:  M Pignone; R Harris; L Kinsinger
Journal:  Ann Intern Med       Date:  2000-11-21       Impact factor: 25.391

9.  Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey.

Authors:  Louie E Ross; Zahava Berkowitz; Donatus U Ekwueme
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

10.  Preferences of husbands and wives for outcomes of prostate cancer screening and treatment.

Authors:  Robert J Volk; Scott B Cantor; Alvah R Cass; Stephen J Spann; Susan C Weller; Murray D Krahn
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

View more
  6 in total

1.  National evidence on the use of shared decision making in prostate-specific antigen screening.

Authors:  Paul K J Han; Sarah Kobrin; Nancy Breen; Djenaba A Joseph; Jun Li; Dominick L Frosch; Carrie N Klabunde
Journal:  Ann Fam Med       Date:  2013 Jul-Aug       Impact factor: 5.166

Review 2.  PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making.

Authors:  Lionne D F Venderbos; Monique J Roobol
Journal:  Asian J Androl       Date:  2011-02-07       Impact factor: 3.285

3.  A randomized trial of a computer-tailored decision aid to improve prostate cancer screening decisions: results from the Take the Wheel trial.

Authors:  Jennifer D Allen; Megan K D Othus; Alton Hart; Laura Tom; Yi Li; Donna Berry; Deborah Bowen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-17       Impact factor: 4.254

4.  Development of a fragile X syndrome (FXS) knowledge scale: towards a modified multidimensional measure of informed choice for FXS population carrier screening.

Authors:  Alice G Ames; Alice Jaques; Obioha C Ukoumunne; Alison D Archibald; Rony E Duncan; Jon Emery; Sylvia A Metcalfe
Journal:  Health Expect       Date:  2012-10-15       Impact factor: 3.377

5.  African American Women's Involvement in Promoting Informed Decision-Making for Prostate Cancer Screening Among Their Partners/Spouses.

Authors:  Jennifer D Allen; Ifedayo C Akinyemi; Amanda Reich; Sasha Fleary; Shalini Tendulkar; Nadeerah Lamour
Journal:  Am J Mens Health       Date:  2018-01-04

6.  The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.

Authors:  Jacob Fredsøe; Jan Koetsenruyter; Peter Vedsted; Pia Kirkegaard; Michael Væth; Adrian Edwards; Torben F Ørntoft; Karina D Sørensen; Flemming Bro
Journal:  PLoS Med       Date:  2020-02-07       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.